The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Synthetic LXR ligand inhibits the development of atherosclerosis in mice
Open accessAbstract
The nuclear receptors LXRα and LXRβ have been implicated in the control of cholesterol and fatty acid metabolism in multiple cell types. Activation of these receptors stimulates cholesterol efflux in macrophages, promotes bile acid synthesis in liver, and inhibits intestinal cholesterol absorption, actions that would collectively be expected to reduce atherosclerotic risk. However, synthetic LXR ligands have also been shown to induce lipogenesis and hypertriglyceridemia in mice, raising questions as to the net effects of these compounds on the development of cardiovascular disease. We demonstrate here that the nonsteroidal LXR agonist GW3965 has potent antiatherogenic activity in two different murine models. In LDLR −/− mice, GW3965 reduced lesion area by 53% in males and 34% in females. A similar reduction of 47% was observed in male apoE −/− mice. Long-term (12-week) treatment with LXR agonist had differential effects on plasma lipid profiles in LDLR −/− and apoE −/− mice. GW3965 induced expression of ATP-binding cassettes A1 and G1 in modified low-density lipoprotein-loaded macrophages in vitro as well as in the aortas of hyperlipidemic mice, suggesting that direct actions of LXR ligands on vascular gene expression are likely to contribute to their antiatherogenic effects. These observations provide direct evidence for an atheroprotective effect of LXR agonists and support their further evaluation as potential modulators of human cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein E
Zhang, S. H., Reddick, R. L., Piedrahita, J. A., & Maeda, N. (1992) · Science · doi:10.1126/science.1411543 · Cited by 2,237
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., & Spiegelman, B. M. (1994) · Genes & Development · doi:10.1101/gad.8.10.1224 · Cited by 2,181
Self-citationPPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797
Self-citationRepa, J. J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.-M. A., Shimomura, I., Shan, B., Brown, M. S., Goldstein, J. L., & Mangelsdorf, D. J. (2000) · Genes & Development · doi:10.1101/gad.844900 · Cited by 1,692
Berge, K. E., Tian, H., Graf, G. A., Yu, L., Grishin, N. V., Schultz, J., Kwiterovich, P., Shan, B., Barnes, R., & Hobbs, H. H. (2000) · Science · doi:10.1126/science.290.5497.1771 · Cited by 1,648
An oxysterol signalling pathway mediated by the nuclear receptor LXRα
Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R., & Mangelsdorf, D. J. (1996) · Nature · doi:10.1038/383728a0 · Cited by 1,591
Role of LXRs in control of lipogenesis
Schultz, J. R., Tu, H., Luk, A., Repa, J. J., Medina, J. C., Li, L., Schwendner, S., Wang, S., Thoolen, M., Mangelsdorf, D. J., et al. (2000) · Genes & Development · doi:10.1101/gad.850400 · Cited by 1,499
Peet, D. J., Turley, S. D., Ma, W., Janowski, B. A., Lobaccaro, J.-M. A., Hammer, R. E., & Mangelsdorf, D. J. (1998) · Cell · doi:10.1016/s0092-8674(00)81432-4 · Cited by 1,436
A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis
Chawla, A., Boisvert, W. A., Lee, C.-H., Laffitte, B. A., Barak, Y., Joseph, S. B., Liao, D., Nagy, L., Edwards, P. A., Curtiss, L. K., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00164-2 · Cited by 1,347
Self-citationRegulation of Absorption and ABC1-Mediated Efflux of Cholesterol by RXR Heterodimers
Repa, J. J., Turley, S. D., Lobaccaro, J.-M. A., Medina, J., Li, L., Lustig, K., Shan, B., Heyman, R. A., Dietschy, J. M., & Mangelsdorf, D. J. (2000) · Science · doi:10.1126/science.289.5484.1524 · Cited by 1,301
Cited by
Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J., & Tontonoz, P. (2003) · Nature Medicine · doi:10.1038/nm820 · Cited by 1,158
Self-citationMacrophage death and defective inflammation resolution in atherosclerosis
Tabas, I. (2010) · Nature Reviews Immunology · doi:10.1038/nri2675 · Cited by 1,120
New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport
Lewis, G. F., & Rader, D. J. (2005) · Circulation Research · doi:10.1161/01.res.0000170946.56981.5c · Cited by 1,093
Liver X receptors as integrators of metabolic and inflammatory signaling
Zelcer, N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27883 · Cited by 978
Transcriptional Regulation of Metabolism
Desvergne, B., Michalik, L., & Wahli, W. (2006) · Physiological Reviews · doi:10.1152/physrev.00025.2005 · Cited by 892
LXR Regulates Cholesterol Uptake Through Idol-Dependent Ubiquitination of the LDL Receptor
Zelcer, N., Hong, C., Boyadjian, R., & Tontonoz, P. (2009) · Science · doi:10.1126/science.1168974 · Cited by 848
Self-citationIntegration of metabolism and inflammation by lipid-activated nuclear receptors
Bensinger, S. J., & Tontonoz, P. (2008) · Nature · doi:10.1038/nature07202 · Cited by 810
Self-citationTranscriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR
Calkin, A. C., & Tontonoz, P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3312 · Cited by 779
“LXR activation with GW3965 strongly attenuates atherosclerosis in the two most common models — the Apoe -null mouse and the Ldlr -null mous”
Self-citationLiver X receptors in lipid signalling and membrane homeostasis
Wang, B., & Tontonoz, P. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0037-x · Cited by 722
Self-citationLXR signaling couples sterol metabolism to proliferation in the acquired immune response
Bensinger, S. J., Bradley, M. N., Joseph, S. B., Zelcer, N., Janssen, E. M., Hausner, M. A., Shih, R., Parks, J. S., Edwards, P. A., Jamieson, B. D., et al. (2008) · Cell · doi:10.1016/j.cell.2008.04.052 · Cited by 711
Self-citationThe macrophage foam cell as a target for therapeutic intervention
Li, A. C., & Glass, C. K. (2002) · Nature Medicine · doi:10.1038/nm1102-1235 · Cited by 700
Rayner, K. J., Sheedy, F. J., Esau, C. C., Hussain, F. N., Temel, R. E., Parathath, S., van Gils, J. M., Rayner, A. J., Chang, A. N., Suarez, Y., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57275 · Cited by 690
Nuclear Receptors and the Control of Metabolism
Francis, G. A., Fayard, E., Picard, F., & Auwerx, J. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142528 · Cited by 636
Liver X Receptor Signaling Pathways in Cardiovascular Disease
Tontonoz, P., & Mangelsdorf, D. J. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0061 · Cited by 633
Self-citationLXRS AND FXR: The Yin and Yang of Cholesterol and Fat Metabolism
Kalaany, N. Y., & Mangelsdorf, D. J. (2006) · Annual Review of Physiology · doi:10.1146/annurev.physiol.68.033104.152158 · Cited by 615
Molecular regulation of HDL metabolism and function: implications for novel therapies
Rader, D. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci30163 · Cited by 599
The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis
Rader, D. J., Alexander, E. T., Weibel, G. L., Billheimer, J., & Rothblat, G. H. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800088-jlr200 · Cited by 597
Liver X receptors in lipid metabolism: opportunities for drug discovery
Hong, C., & Tontonoz, P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4280 · Cited by 587
Self-citationTranscriptional Repression of Atherogenic Inflammation: Modulation by PPARδ
Lee, C.-H., Chawla, A., Urbiztondo, N., Liao, D., Boisvert, W. A., & Evans, R. M. (2003) · Science · doi:10.1126/science.1087344 · Cited by 580
Li, A. C., Binder, C. J., Gutierrez, A., Brown, K. K., Plotkin, C. R., Pattison, J. W., Valledor, A. F., Davis, R. A., Willson, T. M., Witztum, J. L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci18730 · Cited by 573
Self-citationMechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids
Adkins, Y., & Kelley, D. S. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.12.004 · Cited by 557
Lipid Metabolism in Regulation of Macrophage Functions
Yan, J., & Horng, T. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.09.006 · Cited by 553
Rong, J. X., Shapiro, M., Trogan, E., & Fisher, E. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1735526100 · Cited by 551
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
Structural Overview of the Nuclear Receptor Superfamily: Insights into Physiology and Therapeutics
Huang, P., Chandra, V., & Rastinejad, F. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135917 · Cited by 533
Mouse Models for Atherosclerosis and Pharmaceutical Modifiers
Zadelaar, S., Kleemann, R., Verschuren, L., de Vries-Van der Weij, J., van der Hoorn, J., Princen, H. M., & Kooistra, T. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.142570 · Cited by 527
Macrophage Reverse Cholesterol Transport: Key to the Regression of Atherosclerosis?
Cuchel, M., & Rader, D. J. (2006) · Circulation · doi:10.1161/circulationaha.104.475715 · Cited by 527
The nuclear receptor LXR is a glucose sensor
Mitro, N., Mak, P. A., Vargas, L., Godio, C., Hampton, E., Molteni, V., Kreusch, A., & Saez, E. (2007) · Nature · doi:10.1038/nature05449 · Cited by 524
Oram, J. F., & Heinecke, J. W. (2005) · Physiological Reviews · doi:10.1152/physrev.00005.2005 · Cited by 521
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis
Chen, W., Schilperoort, M., Cao, Y., Shi, J., Tabas, I., & Tao, W. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00629-x · Cited by 518
Translating molecular discoveries into new therapies for atherosclerosis
Rader, D. J., & Daugherty, A. (2008) · Nature · doi:10.1038/nature06796 · Cited by 515
Atherosclerosis in the Apolipoprotein E–Deficient Mouse: A Decade of Progress
Meir, K. S., & Leitersdorf, E. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000128849.12617.f4 · Cited by 498
Dyslipidemia and inflammation: an evolutionary conserved mechanism
Esteve, E., Ricart, W., & Fernández-Real, J. M. (2005) · Clinical Nutrition · doi:10.1016/j.clnu.2004.08.004 · Cited by 492
Castrillo, A., Joseph, S. B., Vaidya, S. A., Haberland, M., Fogelman, A. M., Cheng, G., & Tontonoz, P. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00384-8 · Cited by 488
Self-citationHDL as a target in the treatment of atherosclerotic cardiovascular disease
Linsel-Nitschke, P., & Tall, A. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1658 · Cited by 486
Combinatorial roles of nuclear receptors in inflammation and immunity
Glass, C. K., & Ogawa, S. (2006) · Nature Reviews Immunology · doi:10.1038/nri1748 · Cited by 464
Drugging the efferocytosis process: concepts and opportunities
Mehrotra, P., & Ravichandran, K. S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00470-y · Cited by 459
Tall, A. R. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01898.x · Cited by 436
Liver X receptor in cholesterol metabolism
Zhao, C., & Dahlman-Wright, K. (2010) · Journal of Endocrinology · doi:10.1677/joe-09-0271 · Cited by 418
ATP-Binding Cassette Cholesterol Transporters and Cardiovascular Disease
Oram, J. F., & Vaughan, A. M. (2006) · Circulation Research · doi:10.1161/01.res.0000250171.54048.5c · Cited by 411
Makowski, L., Brittingham, K. C., Reynolds, J. M., Suttles, J., & Hotamisligil, G. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413788200 · Cited by 410
Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
Haas, J. T., Francque, S., & Staels, B. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105331 · Cited by 394
The liver X receptor gene team: Potential new players in atherosclerosis
Repa, J. J., & Mangelsdorf, D. J. (2002) · Nature Medicine · doi:10.1038/nm1102-1243 · Cited by 388
Retinoid X Receptor Heterodimers in the Metabolic Syndrome
Shulman, A. I., & Mangelsdorf, D. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043590 · Cited by 380
Pharmacological Activation of Liver X Receptors Promotes Reverse Cholesterol Transport In Vivo
Naik, S. U., Wang, X., Da Silva, J. S., Jaye, M., Macphee, C. H., Reilly, M. P., Billheimer, J. T., Rothblat, G. H., & Rader, D. J. (2006) · Circulation · doi:10.1161/circulationaha.105.560177 · Cited by 378
Self-citationTang, J.-J., Li, J.-G., Qi, W., Qiu, W.-W., Li, P.-S., Li, B.-L., & Song, B.-L. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2010.12.004 · Cited by 365
Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming
Zimmer, S., Grebe, A., Bakke, S. S., Bode, N., Halvorsen, B., Ulas, T., Skjelland, M., De Nardo, D., Labzin, L. I., Kerksiek, A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6100 · Cited by 360
PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis
Li, A. C., & Glass, C. K. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400010-jlr200 · Cited by 357
Fatty Acid Regulation of Gene Transcription
Jump, D. B. (2004) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360490278341 · Cited by 356
Atheroprotective Effects of High-Density Lipoproteins
Assmann, G., & Nofer, J.-R. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152409 · Cited by 343
An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers
Villa, G. R., Hulce, J. J., Zanca, C., Bi, J., Ikegami, S., Cahill, G. L., Gu, Y., Lum, K. M., Masui, K., Yang, H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.008 · Cited by 325
Self-citationTargeting SREBP-1-driven Lipid Metabolism to Treat Cancer
Guo, D., Bell, E., Mischel, P., & Chakravarti, A. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990486 · Cited by 323
Liver X Receptor-dependent Repression of Matrix Metalloproteinase-9 Expression in Macrophages
Castrillo, A., Joseph, S. B., Marathe, C., Mangelsdorf, D. J., & Tontonoz, P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213071200 · Cited by 318
Self-citationThe clearance of dying cells: table for two
Green, D. R., Oguin, T. H., & Martinez, J. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.172 · Cited by 314
Clinical Utility of Bile Acid Sequestrants in the Treatment of Dyslipidemia: A Scientific Review
Insull, W. (2006) · Southern Medical Journal · doi:10.1097/01.smj.0000208120.73327.db · Cited by 308
Fernández-Hernando, C., Suárez, Y., Rayner, K. J., & Moore, K. J. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283428d9d · Cited by 308
Macrophage Differentiation to Foam Cells
Shashkin, P., Dragulev, B., & Ley, K. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612054865064 · Cited by 295
Liver X Receptor Signaling Pathways and Atherosclerosis
Calkin, A. C., & Tontonoz, P. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.191197 · Cited by 293
Self-citationvan Diepen, J. A., Berbée, J. F. P., Havekes, L. M., & Rensen, P. C. N. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.02.028 · Cited by 292
Macrophage Liver X Receptor Is Required for Antiatherogenic Activity of LXR Agonists
Levin, N., Bischoff, E. D., Daige, C. L., Thomas, D., Vu, C. T., Heyman, R. A., Tangirala, R. K., & Schulman, I. G. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000150044.84012.68 · Cited by 284
Nuclear Receptors and Their Selective Pharmacologic Modulators
Burris, T. P., Solt, L. A., Wang, Y., Crumbley, C., Banerjee, S., Griffett, K., Lundasen, T., Hughes, T., & Kojetin, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006833 · Cited by 283
Pei, L., Castrillo, A., Chen, M., Hoffmann, A., & Tontonoz, P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502606200 · Cited by 281
Self-citationSvensson, S. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg456 · Cited by 278
Wang, N., Chen, W., Linsel-Nitschke, P., Martinez, L. O., Agerholm-Larsen, B., Silver, D. L., & Tall, A. R. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16808 · Cited by 277
Putnam, K., Shoemaker, R., Yiannikouris, F., & Cassis, L. A. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00796.2011 · Cited by 273
Abildayeva, K., Jansen, P. J., Hirsch-Reinshagen, V., Bloks, V. W., Bakker, A. H. F., Ramaekers, F. C. S., de Vente, J., Groen, A. K., Wellington, Kuipers, F., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601019200 · Cited by 267
Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation
Castrillo, A., & Tontonoz, P. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.012103.134432 · Cited by 260
Self-citationWang, N., & Tall, A. R. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000075912.83860.26 · Cited by 258
Shin, S., Ha, T., McGregor, R. A., & Choi, M. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100440 · Cited by 257
ATP-Binding Cassette Transporters, Atherosclerosis, and Inflammation
Westerterp, M., Bochem, A. E., Yvan-Charvet, L., Murphy, A. J., Wang, N., & Tall, A. R. (2014) · Circulation Research · doi:10.1161/circresaha.114.300738 · Cited by 257
Phenotypic Polarization of Macrophages in Atherosclerosis
Leitinger, N., & Schulman, I. G. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300173 · Cited by 256
Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors
Hong, C., & Tontonoz, P. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.07.016 · Cited by 253
Self-citationLiver X receptors link lipid metabolism and inflammation
Schulman, I. G. (2017) · FEBS Letters · doi:10.1002/1873-3468.12702 · Cited by 244
The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease
Fessler, M. B. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.010 · Cited by 173
Kirchgessner, T. G., Sleph, P., Ostrowski, J., Lupisella, J., Ryan, C. S., Liu, X., Fernando, G., Grimm, D., Shipkova, P., Zhang, R., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.07.016 · Cited by 172
Liver X receptors as regulators of macrophage inflammatory and metabolic pathways
A-González, N., & Castrillo, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.12.015 · Cited by 139
Liver X receptors (LXR) as therapeutic targets in dyslipidemia
Bełtowski, J. (2008) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2008.00062.x · Cited by 132
Kim, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-07381-8 · Cited by 126
Brunham, L. R., Kruit, J. K., Pape, T. D., Parks, J. S., Kuipers, F., & Hayden, M. R. (2006) · Circulation Research · doi:10.1161/01.res.0000244014.19589.8e · Cited by 118
Zhang-Gandhi, C. X., & Drew, P. D. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.007 · Cited by 117
Gromovsky, A. D., Schugar, R. C., Brown, A. L., Helsley, R. N., Burrows, A. C., Ferguson, D., Zhang, R., Sansbury, B. E., Lee, R. G., Morton, R. E., et al. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309660 · Cited by 115
HDL from an Alzheimer's disease perspective
Button, E. B., Robert, J., Caffrey, T. M., Fan, J., Zhao, W., & Wellington, C. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000604 · Cited by 114
Greasing the wheels of Aβ clearance in Alzheimer's Disease: The role of lipids and apolipoprotein E
Fan, J., Donkin, J., & Wellington, C. (2009) · BioFactors · doi:10.1002/biof.37 · Cited by 97
LXRα Regulates Macrophage Arginase 1 Through PU.1 and Interferon Regulatory Factor 8
Pourcet, B., Feig, J. E., Vengrenyuk, Y., Hobbs, A. J., Kepka-Lenhart, D., Garabedian, M. J., Morris, S. M., Fisher, E. A., & Pineda-Torra, I. (2011) · Circulation Research · doi:10.1161/circresaha.111.241810 · Cited by 97
Lipid metabolism and neuroinflammation in Alzheimer’s disease: a role for liver X receptors
Kang, J., & Rivest, S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1049 · Cited by 94
Bischoff, E. D., Daige, C. L., Petrowski, M., Dedman, H., Pattison, J., Juliano, J., Li, A. C., & Schulman, I. G. (2010) · The Journal of Lipid Research · doi:10.1194/jlr.m900096 · Cited by 91
ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition
Chen, Y. Q., Pottanat, T. G., Zhen, E. Y., Siegel, R. W., Ehsani, M., Qian, Y.-W., & Konrad, R. J. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100068 · Cited by 82
Töröcsik, D., Szanto, A., & Nagy, L. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.02.002 · Cited by 82
HDL-cholesterol and cardiovascular disease: rethinking our approach
Siddiqi, H. K., Kiss, D., & Rader, D. (2015) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000211 · Cited by 77
Wang, Y. Y., Dahle, M. K., Ågren, J., Myhre, A. E., Reinholt, F. P., Foster, S. J., Collins, J. L., Thiemermann, C., Aasen, A. O., & Wang, J. E. (2006) · Shock · doi:10.1097/01.shk.0000191377.78144.d9 · Cited by 76
Self-citationNoghero, A., Perino, A., Seano, G., Saglio, E., Sasso, G. L., Veglio, F., Primo, L., Hirsch, E., Bussolino, F., & Morello, F. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.250621 · Cited by 73
Ma, Z., Deng, C., Hu, W., Zhou, J., Fan, C., Di, S., Liu, D., Yang, Y., & Wang, D. (2017) · Current Issues in Molecular Biology · doi:10.21775/cimb.022.041 · Cited by 70
Inhibition of cholesterol biosynthesis through RNF145-dependent ubiquitination of SCAP
Zhang, L., Rajbhandari, P., Priest, C., Sandhu, J., Wu, X., Temel, R., Castrillo, A., de Aguiar Vallim, T. Q., Sallam, T., & Tontonoz, P. (2017) · eLife · doi:10.7554/elife.28766 · Cited by 69
Self-citationNagenborg, J., Goossens, P., Biessen, E. A. L., & Donners, M. M. P. C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.005 · Cited by 50
Gu, H.-M., Wang, F.-Q., & Zhang, D.-W. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.02.002 · Cited by 39
Yoon, H.-S., Ju, J.-H., Kim, H.-N., Park, H.-J., Ji, Y., Lee, J.-E., Shin, H.-K., Do, M.-S., & Holzapfel, W. (2013) · International Journal of Food Sciences and Nutrition · doi:10.3109/09637486.2012.706598 · Cited by 38
“The non-steroidal LXR agonists GW3965 hydrochloride (Joseph et al. 2002) and TO901317 (Zhang et al.”
BackgroundmiR‐33 in cardiometabolic diseases: lessons learned from novel animal models and approaches
Price, N. L., Goedeke, L., Suárez, Y., & Fernández‐Hernando, C. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012606 · Cited by 36
Ramírez, C. M., Torrecilla-Parra, M., Pardo-Marqués, V., de-Frutos, M. F., Pérez-García, A., Tabraue, C., de la Rosa, J. V., Martín-Rodriguez, P., Díaz-Sarmiento, M., Nuñez, U., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.635923 · Cited by 34
The macrophage LBP gene is an LXR target that promotes macrophage survival and atherosclerosis
Sallam, T., Ito, A., Rong, X., Kim, J., van Stijn, C., Chamberlain, B. T., Jung, M. E., Chao, L. C., Jones, M., Gilliland, T., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m047548 · Cited by 30
Self-citationJan, A., Karasinska, J. M., Kang, M. H., de Haan, W., Ruddle, P., Kaur, A., Connolly, C., Leavitt, B. R., Sorensen, P. H., & Hayden, M. R. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.05.007 · Cited by 28
Metadata
- Authors
- Joseph, S. B., McKilligin, E., Pei, L., Watson, M. A., Collins, A. R., Laffitte, B. A., Chen, M., Noh, G., Goodman, J., Hagger, G. N., Tran, J., Tippin, T. K., Wang, X., Lusis, A. J., Hsueh, W. A., Law, R. E., Collins, J. L., Willson, T. M., & Tontonoz, P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2002-05-14
- Volume
- 99
- Issue
- 11
- Pages
- 7604-7609
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2159332620
- Cited by
- 947
- References
- 32
- FWCI
- 39.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.